EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics
Portfolio Pulse from Vandana Singh
Lineage Cell Therapeutics Inc (LCTX) has started development activities under its exclusive license agreement with Eterna Therapeutics Inc (ERNA) to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line. This is part of a strategic collaboration announced in February 2023, where Eterna is developing engineered hypoimmune iPSC lines that Lineage will evaluate for differentiation into cell transplant product candidates for central nervous system diseases and other neurology indications. Lineage will make payments to Eterna in connection with Eterna’s successful development and delivery of certain materials.
September 06, 2023 | 11:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eterna Therapeutics is collaborating with Lineage Cell Therapeutics under a license agreement. Eterna will conduct gene-editing activities and provide materials to Lineage for evaluation, and will receive payments from Lineage for successful development and delivery of certain materials.
The collaboration with Lineage Cell Therapeutics could potentially increase Eterna's revenues and profitability in the long run. The successful development and delivery of certain materials to Lineage could also enhance Eterna's reputation in the industry.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Lineage Cell Therapeutics has initiated development activities under its license agreement with Eterna Therapeutics. This could potentially expand Lineage's technology to new areas and differentiate its cell line from competitors.
The initiation of development activities under the license agreement with Eterna Therapeutics could potentially expand Lineage's technology to new areas and differentiate its cell line from competitors. This could potentially increase the company's market share and profitability in the long run.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100